Research & Diagnostic Antibodies Receives Notice of Allowance for Second Key Sepsis Diagnostic Patent in Japan
7/26/2012 10:03:10 AM
LAS VEGAS--(BUSINESS WIRE)--Research & Diagnostic Antibodies (R&D Antibodies) announced today that it has received a Notice of Allowance from the Japan Patent Office for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology. Japanese Patent Application #2003-517204 covers very broadly the use of R&D Antibodies’ immunoassays, assay kits, and apparatuses for the detection of plasma iNOS as an early biomarker for the prognosis and diagnosis of the life-threatening sepsis pathology. The JPO’s Allowance extends R&D Antibodies’ existing patent portfolio in this field (USA #6531578-B1 and 7198904-B1; European #EP1012605 and EP1412471; Japan #4117911; and Australian #2001280912 and 782922). Additional patent applications are pending.